三個皮匠報告
政策庫
new
付費
搜索

戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比-行業數據

戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比
characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases》Scuron, M. et al. 2020，《CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms》Tyner, J. et, al. 2010，華泰研究
行業數據 下載Excel 下載圖片 原圖定位
圖片屬性
圖片格式：PNG 圖片大?。?9KB 圖片尺寸：1819*252
同報告圖片
 / 54
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第1頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第2頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第3頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第4頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第5頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第6頁
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第7頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第8頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第9頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第10頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第11頁
fCDlm73kuqfljZXkuIDliJvmlrDoja/lr7nlpJbmjojmnYPmjpLooYzvvIjpppbku5jmrL7vvIkgfCDph5Hpop3vvIjkur/nvo7lhYPvvIkgfAp8LS0tfC0tLXwKfCDnmb7mtY7npZ7lt54t6K+65Y2O77yI5pu/6Zu35Yip54+g5Y2V5oqX77yJIHwgNi41IHwKfCDkvKDlpYfnlJ/niakt5by655Sf77yITENBUi1CMzhN77yJIHwgMy41IHwKfCDnmb7mtY7npZ7lt54t6K+65Y2O77yIb2NpcGVybGltYWLvvIkgfCAzLjAgfAp8IOiNo+aYjOeUn+eJqS3opb/pm4Xlm77ln7rlm6DvvIjnu7Tov6ropb/lpqXljZXmipfvvIkgfCAyLjAgfAp8IOS/oei+vueUn+eJqS3npLzmnaXvvIjkv6Hov6rliKnljZXmipfvvIkgfCAyLjAgfAoK6LWE5paZ5p2l5rqQ77ya5ZCE5YWs5Y+45YWs5ZGK77yM5Y2O5rOw56CU56m2
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第12頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第13頁
fCDpgJrnlKjlkI0gfCDlnLDljLogfCDkuIrluILmiJDlip/njocgfCAyMDIzRSB8IDIwMjRFIHwgMjAyNUUgfCAyMDI2RSB8IDIwMjdFIHwgMjAyOEUgfCAyMDI5RSB8IDIwMzBFIHwgMjAzMUUgfAp8LS0tLS0tfC0tLS0tLXwtLS0tLS0tLS0tfC0tLS0tLS18LS0tLS0tLXwtLS0tLS0tfC0tLS0tLS18LS0tLS0tLXwtLS0tLS0tfC0tLS0tLS18LS0tLS0tLXwtLS0tLS0tfAp8IERaRDkwMDggfCDkuK3lm70gIHwgODUlICAgICAgfCAyLjI4ICB8IDYuMjMgIHwgMTEuNTQgfCAxNy41NyB8IDE2LjM0IHwgMjAuMzAgfCAyMy4wNiB8IDI1LjA1IHwgMjQuMzggfAp8ICAgICAgfCDnvo7lm70gIHwgODAlICAgICAgfCAgICAgICB8IDMuMTQgIHwgMTQuMzcgfCAyNS44MCB8IDM1LjA4IHwgNDQuMjggfCA1MS43NyB8IDUxLjA0IHwgICAgICAgfAp8ICAgICAgfCDmtbflpJblhbbku5YgfCA4MCUgICAgICB8ICAgICAgIHwgMS41NyAgfCA3LjE4ICB8IDEyLjkwIHwgMTcuNTQgfCAyMi4xNCB8IDI1Ljg4IHwgMjUuNTIgfCAgICAgICB8Cnwg5ZCI6K6hICB8ICAgICAgfCAgICAgICAgICB8IDIuMjggIHwgNi4yMyAgfCAxNi4yNSB8IDM5LjEzIHwgNTUuMDQgfCA3Mi45MyB8IDg5LjQ4IHwgMTAyLjcxIHwgMTAwLjk0IHwKCui1hOaWmeadpea6kDogRnJvc3QgJiBTdWxsaXZhbiwg5Yy76I2v6a2U5pa5LCBQREIsIEV2YWx1YXRlIFBoYXJtYSwg5Y2O5rOw56CU56m26aKE5rWL
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第14頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第15頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第16頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第17頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第18頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第19頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第20頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第21頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第22頁
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第23頁
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第24頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第25頁
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第26頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第27頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第28頁
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第29頁
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第30頁
fCDlubTku70gfCDljY7otLnotLnnlKjvvIjkuIflhYMv5bm077yJIHwg6LS555So5Y+Y5Yqo77yIJe+8iSB8IOS4reWbveS6uuWPo+aAu+aVsO+8iOS4h+S6uu+8iSB8IOS6uuWPo+WinumAn++8iCXvvIkgfCDlpJblkahU57uG6IOe5reL5be055ik77yIUFRDTO+8iSB8IFBUQ0zmlrDmhJ/kurrmlbDvvIjkuIfkurrvvIkgfCBOSEnlj5Hnl4XnjofvvIgxLzEw5LiH77yJIHwgUFRDTOWNoOavlO+8iCXvvIkgfCBQVENMIDFM57u05oyBIHwgMUzmsrvnlpfnjofvvIgl77yJIHwgSkFLMeaKkeWItuWJguWNoOavlO+8iCXvvIkgfCBEWkQ0MjA15Lu96aKd77yIJe+8iSB8IOayu+eWl+aXtumVv++8iOaciO+8iSB8IFBUQ0wgMUznu7TmjIHplIDllK7pop3vvIjkur/lhYPvvIkgfCBQVENM5aSN5Y+R5rK755aXIHwgcnJQVENM5paw5oSf5Lq65pWw77yI5LiH5Lq677yJIHwg5aSN5Y+R6Zq+5rK75q+U5L6L77yIJe+8iSB8IOayu+eWl+eOh++8iCXvvIkgfCBKQUsx5oqR5Yi25YmC5Y2g5q+U77yIJe+8iSB8IERaRDQyMDXku73pop3vvIgl77yJIHwg5rK755aX5pe26ZW/77yI5pyI77yJIHwgUFRDTOWkjeWPkeayu+eWl+mUgOWUrumine+8iOS6v+WFg++8iSB8IERaRDQyMDUtUFRDTOmUgOWUrumine+8iOS6v+WFg++8iSB8IOS4iuW4guaIkOWKn+eOh++8iCXvvIkgfCBEWkQ0MjA1LVBUQ0zpo47pmanosIPmlbTlkI7plIDllK7pop3vvIjkur/lhYPvvIkgfCDnmq7ogqRU57uG6IOe5reL5be055ik77yIQ1RDTO+8iSB8IENUQ0zmlrDmhJ/kurrmlbDvvIjljYPkurrvvIkgfCBOSEnlj5Hnl4XnjofvvIgxLzEw5LiH77yJIHwgQ1RDTOWNoOavlO+8iCXvvIkgfCByckNUQ0zmlrDmhJ/kurrmlbDvvIjljYPkurrvvIkgfCDlpI3lj5Hpmr7msrvmr5TkvovvvIgl77yJIHwg5rK755aX546H77yIJe+8iSB8IEpBSzHmipHliLbliYLljaDmr5TvvIgl77yJIHwgRFpENDIwNeS7vemine+8iCXvvIkgfCDmsrvnlpfml7bplb/vvIjmnIjvvIkgfCBEWkQ0MjA1LUNUQ0zplIDllK7pop3vvIjkur/lhYPvvIkgfCDkuIrluILmiJDlip/njofvvIgl77yJIHwgRFpENDIwNS1DVENM6aOO6Zmp6LCD5pW05ZCO6ZSA5ZSu6aKd77yI5Lq/5YWD77yJIHwKfC0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tfAp8IDIwMjFBIHwgNTAuMCB8IC01MCUgfCAxNDEsMTc4IHwgMC4zJSB8IDIuNCB8IDYuNzEgfCAyNSUgfCA5MCUgfCAxLjAlIHwgMTAwJSB8IDE1IHwgMS40IHwgMC43IHwgMi4xIHwgMy44IHwgNi43MSB8IDQlIHwgMi43IHwgNzAlIHwgOTAlIHwgMS4wJSB8IDEwMCUgfCAxMCB8IDAuMSB8IDYwJSB8IDAuMCB8IDQuMiB8IDcuMzMgfCA0JSB8IDIuOSB8IDcwJSB8IDkwJSB8IDUuMCUgfCAxMDAlIHwgMTAgfCAwLjMgfCAwLjIgfCA0LjMgfCA3LjMzIHwgNCUgfCAzLjAgfCA3MCUgfCA5MCUgfCA1LjAlIHwgMTAwJSB8IDEwIHwgMC40IHwgMC4yIHwgNS4wIHwgNy4zMyB8IDQlIHwgMy4yIHwgNzAlIHwgOTAlIHwgNS4wJSB8IDEwMCUgfCAxMCB8IDAuNSB8IDAuMiB8IDUuOCB8IDcuMzMgfCA0JSB8IDMuMiB8IDcwJSB8IDkwJSB8IDUuMCUgfCAxMDAlIHwgMTAgfCAwLjYgfCAwLjIgfCA2LjcgfCA3LjMzIHwgNCUgfCAzLjIgfCA3MCUgfCA5MCUgfCA1LjAlIHwgMTAwJSB8IDEwIHwgMC43IHwgMC4yIHwgNy42IHwgNy4zMyB8IDQlIHwgMy4yIHwgNzAlIHwgOTAlIHwgNS4wJSB8IDEwMCUgfCAxMCB8IDAuOCB8IDAuMiB8IDguNSB8IDcuMzMgfCA0JSB8IDMuMiB8IDcwJSB8IDkwJSB8IDUuMCUgfCAxMDAlIHwgMTAgfCAwLjkgfCAwLjIgfCA5LjQgfCA3LjMzIHwgNCUgfCAzLjIgfCA3MCUgfCA5MCUgfCA1LjAlIHwgMTAwJSB8IDEwIHwgMS4wIHwgMC4yIHwgMTAuMyB8IDcuMzMgfCA0JSB8IDMuMiB8IDcwJSB8IDkwJSB8IDUuMCUgfCAxMDAlIHwgMTAgfCAxLjEgfCAwLjIgfCAxMS4yIHwgNy4zMyB8IDQlIHwgMy4=
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第31頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第32頁
fCDlp5PlkI0gICB8IOiBjOS9jSAgICAgICAgICAgICAgICAgICAgICAgfCDnu4/pqowgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8CnwtLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tfAp8IOW8oOWwj+ael+WNmuWjqyB8IOWIm+Wni+S6ui/okaPkuovplb8vQ0VPICAgICAgICAgICB8IOaLpeaciei/kTMw5bm05YWo55CD5Yib5paw6I2v56CU5Y+R566h55CG57uP6aqMICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8Cnwg5pu+5bqG5YyX5Y2a5aOrIHwg6aaW5bit56eR5a2m5a62ICAgICAgICAgICAgICAgICAgfCDmi6XmnInotoXov4cyMOW5tOeahOWFqOeQg+WIm+aWsOiNr+iuvuiuoeS4jueglOWPkee7j+mqjCAgICAgICAgICAgICAgICAgICAgICAgIHwKfCDlkJXmtKrmlowgIHwgQ0ZPL+iRo+enmCAgICAgICAgICAgICAgICAgICB8IDIw5bm05oqV6LWE6ZO26KGM55u45YWz57uP6aqMICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8Cnwg5b6Q5rGJ5b+g5Y2a5aOrIHwg6I2v54mp5YyW5a2m6auY57qn5Ymv5oC76KOBICAgICAgICAgICB8IOaLpeaciei2hei/hzE15bm055qE5YWo55CD5Yib5paw6I2v56CU5Y+R5Y+K566h55CG57uP6aqMICAgICAgICAgICAgICAgICAgICAgICAgfAp8IOWQtOa4hea8qiAgfCDpppbluK3llYbliqHlrpggICAgICAgICAgICAgICAgICB8IOaLpeaciei2hei/hzIw5bm055qE5biC5Zy65ZKM6ZSA5ZSu57uP6aqMICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwKfCDlvKDkuJboi7HljZrlo6sgfCDljJblraYv55Sf5LqnL+i0qOmHj+aOp+WItuWJr+aAu+ijgSAgICAgfCDmi6XmnIkyMOW5tOWIm+aWsOiNr+WItuWJguW8gOWPkeOAgeaKgOacr+i9rOenu+OAgeS4tOW6iueUn+S6p+e7j+mqjCAgICAgICAgICAgICAgICAgfAp8IOmZiOe0oOWLpCAgfCDkuLTluorov5DokKXpq5jnuqflia/mgLvoo4EgICAgICAgICAgIHwg5oul5pyJ6LaF6L+HMjDlubTkuLTluorov5DokKXlj4rnrqHnkIbnu4/pqowgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwKfCDlvKDnn6XkuLogIHwg6L+Q6JCl5Ymv5oC76KOBICAgICAgICAgICAgICAgICAgfCDmi6XmnInov5ExNeW5tOeahOWMu+eWl+WMu+iNr+ihjOS4mueuoeeQhue7j+mqjCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwKCui1hOaWmeadpea6kO+8mui/quWTsuWMu+iNr+aLm+iCoeivtOaYjuS5pu+8jOWNjuazsOeglOeptg==
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第33頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第34頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第35頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第36頁
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第37頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第38頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第39頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第40頁
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第41頁
fCDkuLvopoHnq57kuonkuqflk4EgfCDmiYDlsZ7lhazlj7ggfCBwSEVSMiBJQzUwKG5NKSBpbiBCVDQ3NCBjZWxscyB8IHBFR0ZSIElDNTAobk0pIGluIEg4MzggY2VsbHMgfCDph47nlJ/lnosgRUdGUiDkuI4gSEVSMiDnmoTpgInmi6nmgKflgI3mlbAgfAp8LS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS18CnwgRFpEMTUxNiAgICAgIHwg6L+q5ZOy5Yy76I2vIHwgNC40ICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgMS40NTUgICAgICAgICAgICAgICAgICAgICAgICB8IDMzMCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8Cnwg5ouJ5biV5pu/5bC8KExhcGF0aW5pYikgfCDokZvlhbDntKDlj7LlhYsv6K+65Y2OIHwgMi44ICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgOC4xICAgICAgICAgICAgICAgICAgICAgICAgICB8IDIuOSAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8Cnwg5aWI5ouJ5pu/5bC8KE5lcmF0aW5pYikgfCDovonnkZ4gICAgfCAwLjU3ICAgICAgICAgICAgICAgICAgICAgICAgICAgfCAyLjIgICAgICAgICAgICAgICAgICAgICAgICAgIHwgMy45ICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwKfCDlkKHlkq/mm7/lsLwoUHlyb3RpbmliKSB8IOaxn+iLj+aBkueRniB8IDAuNTAgICAgICAgICAgICAgICAgICAgICAgICAgICB8IDMuOCAgICAgICAgICAgICAgICAgICAgICAgICAgfCA3LjYgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfAp8IOWuieWNoeabv+WwvChUdWNhdGluaWIpIHwg6KW/6ZuF5Zu+5Z+65Zug5oqA5pyvIHwgMi40ICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgMywzNDMgICAgICAgICAgICAgICAgICAgICAgICB8IDEsMzkyICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8CnwgVEFTLTA3MjggICAgIHwg5aSn6bmP6I2v5ZOBIHwgMzYgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgNjUgICAgICAgICAgICAgICAgICAgICAgICAgICB8IDEuOCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8CgoK6LWE5paZ5p2l5rqQ77yaS2V2aW4gS29jaCwgMjAxMSBBQUNSIEFubnVhbCBNZWV0aW5nLCDov6rlk7LljLvoja/mi5vogqHor7TmmI7kuaYsIOWNjuazsOeglOeptg==
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第42頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第43頁
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第44頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第45頁
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第46頁
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第47頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第48頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第49頁
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第50頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第51頁
fCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfCAgfA==
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第52頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第53頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第54頁
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
戈利昔替尼（DZD4205）：與已獲批/在研腫瘤適應癥的JAK抑制劑半衰期對比_第55頁
所屬報告： 迪哲醫藥-具備全球競爭力的創新型biotech-221205（39頁）.pdf
打包全文圖表

相關數據

最新數據
聯系我們
  • 0731-84720580
  • sgpjbg002
  • 工作日 9:30 - 18:00
關于我們
侵權處理
關于我們

三個皮匠報告專業的行業報告下載站，每日更新，歡迎大家關注！

copyright@2008-2013 長沙景略智創信息技術有限公司版權所有
網站備案/許可證號：湘B2-20190120

客服
商務合作
小程序
服務號
折疊
午夜网日韩中文字幕,日韩Av中文字幕久久,亚洲中文字幕在线一区二区,最新中文字幕在线视频网站